Mankind Pharma Ltd. Pharma, which went public via an initial public offering (IPO) just last year, has furthered its growth ambition with an acquisition of Bharat Serums And Vaccines Limited (BSV) at an enterprise value of INR136.3bn ($1.6bn) from private equity firm Advent International.
$1.6bn Bharat Serums Buy Gives Mankind Dominance In Women's Health, R&D Engine
PE Firm Advent Exits At 22-23x FY25 EBITDA
With an eye-catching $1.6bn deal, Mankind has acquired Bharat Serums and Vaccines to add a high-barrier, specialty business, a credible biologics R&D engine and a complementary portfolio of women’s fertility and health treatments while PE firm Advent finds a profitable exit. What’s next?
More from Business
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.